Drugs / scAAV9.CB.CLN6
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07582484 | Aug 2026 → Aug 2027 expected | ceroid lipofuscinosis, neuronal, 6A | The Charlotte and Gwenyth Gray Foundation | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | scAAV9.CB.CLN6 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07582484 ↗ |
| Known as | scAAV9 | “self-complementary adeno-associated viral vector, serotype 9 (scAAV9), which contains the human CLN6 gene under the control of a hybrid CMV/CB promoter” NCT07582484 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “self-complementary adeno-associated viral vector, serotype 9” NCT07582484 ↗ |
| Route | Intrathecal | “through an injection into the fluid around the spinal cord (intrathecal administration)” NCT07582484 ↗ |